Does nasal CPAP reduce bronchopulmonary dysplasia (BPD)?

D S Patel, A Greenough

    Research output: Contribution to journalEditorialpeer-review

    19 Citations (Scopus)

    Abstract

    Early nasal continuous positive airway pressure (nCPAP) or early surfactant therapy with early extubation onto nCPAP rather than continued mechanical ventilation has been adopted by many centres, particularly in Scandinavia, as part of the treatment of newborns with respiratory distress syndrome. It has been suggested that bronchopulmonary dysplasia is less of a problem in centres adopting such a policy. Results from randomized trials suggest prophylactic or early nCPAP may reduce bronchopulmonary dysplasia (BPD), but further studies are required to determine the relative contributions of an early lung recruitment policy, early surfactant administration and nCPAP in reducing BPD. In addition, the optimum method of generating and delivering CPAP needs to be determined. Conclusion: The efficacy of nCPAP in improving long-term respiratory outcomes needs to be compared with the newer ventilator techniques with the optimum and timing of delivery of surfactant administration
    Original languageEnglish
    Pages (from-to)1314 - 1317
    Number of pages4
    JournalActa Paediatrica
    Volume97
    Issue number10
    DOIs
    Publication statusPublished - Oct 2008

    Fingerprint

    Dive into the research topics of 'Does nasal CPAP reduce bronchopulmonary dysplasia (BPD)?'. Together they form a unique fingerprint.

    Cite this